However, a previous study18 showed ICI plus chemotherapy was associated with survival benefits during the first 6 months in patients with advanced NSCLC with a PD-L1 TPS of 50% or more and also during the first 12 months in those with a PD-L1 TPS of 90% or more compared with ICI monotherapy, which suggested that patients with a higher risk of early mortality or progression with ICI monotherapy may be better suited for ICI plus chemotherapy than ICI monotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.